• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

    8/26/24 12:15:11 PM ET
    $BGLC
    Medical Specialities
    Health Care
    Get the next $BGLC alert in real time by email

    KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC's wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC's commitment to advancing AI-driven healthcare solutions.

    AISB specializes in innovative healthcare technologies, particularly through its flagship platform, aiCMS, which integrates advanced predictive analytics and AI tools to enhance clinical management and patient care. The investment provides BGLC with a significant equity stake in AISB, enabling deeper collaboration between the two companies.

    Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp., stated, "Our investment in Ascension Innovation represents a critical step in expanding our presence in the rapidly growing digital health sector. By leveraging AISB's cutting-edge AI technology, we aim to enhance our genomic screening services and deliver more personalized healthcare solutions to a broader audience."

    This collaboration is expected to create synergies between BGLC's expertise in blood-based genomic screening and AISB's innovative AI-driven platforms. The integration of these technologies will enable healthcare providers to offer more accurate diagnostics and tailored treatments, ultimately improving patient outcomes.

    Andrew Teng, Chief Executive Officer of Ascension Innovation Sdn Bhd, added, "We are excited to partner with BioNexus Gene Lab Corp. and look forward to transforming the healthcare landscape through the integration of advanced AI and genomic technologies."

    The investment is part of BGLC's broader strategy to capitalize on the expanding digital health and AI markets, which are projected to experience significant growth over the coming years. The Management of BGLC continues to monitor and look for opportunities to grow the value of the investment.

    About BioNexus Gene Lab Corp.

    BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a global leader in RNA-based genomic diagnostics, committed to advancing personalized medicine and improving global health outcomes.

    For more information, visit www.bionexusgenelab.com.

    About Ascension Innovation Sdn Bhd

    Ascension Innovation Sdn Bhd is a leading healthcare technology company focused on innovative AI-driven solutions. Visit www.aisb.io for more details.

    Investor Relations

    BioNexus Gene Lab Corporation

    Email: [email protected]



    Get the next $BGLC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGLC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGLC
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioNexus Gene Lab Corp

      10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

      5/15/25 4:30:39 PM ET
      $BGLC
      Medical Specialities
      Health Care
    • BioNexus Gene Lab Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

      4/30/25 11:16:20 AM ET
      $BGLC
      Medical Specialities
      Health Care
    • Amendment: SEC Form 10-K/A filed by BioNexus Gene Lab Corp

      10-K/A - BioNexus Gene Lab Corp (0001737523) (Filer)

      4/29/25 3:22:15 PM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Leadership Updates

    Live Leadership Updates

    See more
    • BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

      KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

      4/30/25 11:25:00 AM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

      KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

      4/30/25 11:25:00 AM ET
      $BGLC
      Medical Specialities
      Health Care
    • BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

      KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company's 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth. Financial Resilience and Market Stability BGLC ended 2024 with a strong cash position of over $4million and total l

      4/15/25 11:00:17 AM ET
      $BGLC
      Medical Specialities
      Health Care
    • BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

      KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation. Through this partnership, BGLC plans to leverage ML Tech's cutting-edge digital asset trading infrastru

      3/7/25 11:00:10 AM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Wong Yee Meng

      3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

      10/4/23 3:57:35 PM ET
      $BGLC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Yap Chee Keong

      3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

      10/4/23 3:57:20 PM ET
      $BGLC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Yew Chak Hua

      3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

      10/4/23 3:57:07 PM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioNexus Gene Lab Corp

      SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)

      10/17/23 11:46:33 AM ET
      $BGLC
      Medical Specialities
      Health Care